Possible association of AstraZeneca vaccines with rare cases of thrombosis identified by the European Medicines Agency, as announced on Wednesday afternoon (07/04) in a press conference, after evaluating the incidents.
Earlier, the South Korea announced that it is temporarily suspending the use of the AstraZeneca vaccine against COVID-19 in citizens under the age of 60, pending its re-evaluation by the European Regulatory Authority.
A global controversy over the effectiveness and side effects of certain coronavirus vaccines has caused some delays in South Korea’s vaccination campaign, which began in late February with the aim of achieving collective immunity in November.
AstraZeneca has said that its studies have not found an increased risk of thromboembolism due to vaccine, millions of doses of which have been administered worldwide.
The World Health Organization and the EMA have said that the benefits outweigh the risks, something that was reiterated today by the European Medicines Agency through the phrase “the benefit / risk balance remains positive”.